Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 1/20 | 0.32 |
| ▸ | HTR6 | P50406 | 1/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9495808 | 0.82 | RET (0.35) | RETHTR6HTR2A | |
| SCHEMBL5033507 | 0.75 | RET (0.35) | RETHTR6HTR2A | |
| SCHEMBL30718139 | 0.75 | RET (0.35) | RETHTR6HTR2A | |
| SCHEMBL5153749 | 0.75 | — | — | |
| SCHEMBL5150736 | 0.74 | — | — | |
| SCHEMBL1680359 | 0.72 | RET (0.38) | RETHTR6HTR2A | |
| SCHEMBL7943595 | 0.72 | KDM4E (0.32) | RETHTR6HTR2A | |
| SCHEMBL6674266 | 0.70 | HTR2A (0.33) | RETHTR6HTR2A | |
| SCHEMBL7635864 | 0.69 | — | — | |
| SCHEMBL1680358 | 0.69 | HTR2A (0.38) | RETHTR6HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3640236-A1 | A METHOD OF PRODUCING INGENOL-3-ANGELATE | LEO LABORATORIES LIMITED (IE) | 2020-04-22 | — | — | EP | disclosed |
| EP-2595948-B1 | A METHOD OF PRODUCING INGENOL-3-ANGELATE | LEO LABORATORIES LTD (IE) | 2019-09-04 | — | — | EP | disclosed |
| US-9676698-B2 | Method of producing ingenol-3-angelate | LEO LABORATORIES LIMITED (IE) | 2017-06-13 | — | — | US | disclosed |
| US-20160280627-A1 | METHOD OF PRODUCING INGENOL-3-ANGELATE | LEO LABORATORIES LIMITED (IE) | 2016-09-29 | — | — | US | disclosed |
| US-9416084-B2 | Method of producing ingenol-3-angelate | LEO LABORATORIES LIMITED (IE) | 2016-08-16 | — | — | US | disclosed |
| US-20150315118-A1 | METHOD OF PRODUCING INGENOL-3-ANGELATE | LEO LABORATORIES LIMITED (IE) | 2015-11-05 | — | — | US | disclosed |
| US-8901356-B2 | Method of producing ingenol-3-angelate | LEO LABORATORIES LIMITED (IE) | 2014-12-02 | — | — | US | disclosed |
| US-20130177952-A1 | METHOD OF PRODUCING INGENOL-3-ANGELATE | Hogberg, Thomas (DK) | 2013-07-11 | — | — | US | disclosed |
| EP-2595948-A1 | A METHOD OF PRODUCING INGENOL-3-ANGELATE | LEO LABORATORIES LIMITED (IE) | 2013-05-29 | — | — | EP | disclosed |
| WO-2012010172-A1 | A METHOD OF PRODUCING INGENOL-3-ANGELATE | LEO PHARMA A/S (DK) | 2012-01-26 | — | — | WO | disclosed |
| US-6355819-B1 | TRANSITION METAL METALLOCENES WITH HETEROATOM 1- OR 3-SUBSTITUTED INDENYL AND INDENYL DERIVATIVE LIGANDS | BOREALIS TECHNOLOGY OY (FI) | 2002-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150315118-A1 | METHOD OF PRODUCING INGENOL-3-ANGELATE | PRKAG3, AMPD3, ERG28 | RET 2271/4885HTR6 3616/4885HTR2A 4519/4885 |
| US-20130177952-A1 | METHOD OF PRODUCING INGENOL-3-ANGELATE | PRKAG3, AMPD3, ERG28 | RET 2271/4885HTR6 3616/4885HTR2A 4519/4885 |
| US-20160280627-A1 | METHOD OF PRODUCING INGENOL-3-ANGELATE | PRKAG3, AMPD3, ERG28 | RET 2271/4885HTR6 3616/4885HTR2A 4519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.